T. Rowe Price Associates’s Lineage Cell Therapeutics LCTX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-72,398
| Closed | -$33K | – | 3104 |
|
|
2025
Q1 | $33K | Sell |
72,398
-35,806
| -33% | -$16.3K | ﹤0.01% | 2972 |
|
|
2024
Q4 | $55K | Hold |
108,204
| – | – | ﹤0.01% | 2919 |
|
|
2024
Q3 | $98K | Sell |
108,204
-57,190
| -35% | -$51.8K | ﹤0.01% | 2823 |
|
|
2024
Q2 | $164K | Buy |
165,394
+4,080
| +3% | +$4.05K | ﹤0.01% | 2638 |
|
|
2024
Q1 | $239K | Buy |
161,314
+70,418
| +77% | +$104K | ﹤0.01% | 2536 |
|
|
2023
Q4 | $100K | Buy |
90,896
+5,560
| +7% | +$6.12K | ﹤0.01% | 2715 |
|
|
2023
Q3 | $101K | Hold |
85,336
| – | – | ﹤0.01% | 2664 |
|
|
2023
Q2 | $121K | Sell |
85,336
-3,764
| -4% | -$5.34K | ﹤0.01% | 2656 |
|
|
2023
Q1 | $134K | Hold |
89,100
| – | – | ﹤0.01% | 2624 |
|
|
2022
Q4 | $104K | Hold |
89,100
| – | – | ﹤0.01% | 2711 |
|
|
2022
Q3 | $101K | Buy |
89,100
+16,700
| +23% | +$18.9K | ﹤0.01% | 2720 |
|
|
2022
Q2 | $114K | Buy |
72,400
+11,309
| +19% | +$17.8K | ﹤0.01% | 2724 |
|
|
2022
Q1 | $94K | Buy |
61,091
+2,700
| +5% | +$4.15K | ﹤0.01% | 2849 |
|
|
2021
Q4 | $143K | Sell |
58,391
-57,300
| -50% | -$140K | ﹤0.01% | 2816 |
|
|
2021
Q3 | $292K | Buy |
115,691
+61,960
| +115% | +$156K | ﹤0.01% | 2583 |
|
|
2021
Q2 | $153K | Buy |
53,731
+9,931
| +23% | +$28.3K | ﹤0.01% | 2773 |
|
|
2021
Q1 | $103K | Buy |
+43,800
| New | +$103K | ﹤0.01% | 2773 |
|